Form 4 CRISPR Therapeutics AG For: Dec 10 Filed by: Bolzon Bradley J PhD

FORM
4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities
Exchange Act of 1934
or Section 30(h) of the Investment Company Act of
1940

OMB APPROVAL

OMB Number: 3235-0287 Expires: December 31, 2014 Estimated average burden hours per response: 0.5